Latest Bristol-Myers Squibb Company (BMY) Headlines
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
BMY May 2nd Options Begin Trading
at The Street - Thu Mar 13, 10:56AM CDT
Investors in Bristol-Myers Squibb Co. saw new options become available today, for the May 2nd expiration.
Early Glance: Pharmaceuticals companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Can Gilead Dominate The HIV Drug Market Again in 2014?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 12, 5:35PM CDT
Gilead's slate of HIV drug therapies helped it capture the bulk of the market in 2013, outpacing competing therapies from Johnson & Johnson and Bristol-Myers . Sales from Gilead's HIV drugs totaled more than $9 billion last year,...
Bristol-Myers Squibb: More Than Just a Relief Rally?
Peter Stephens, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Last week was strong for shares in Bristol-Myers Squibb , which rallied 3% while the S&P 500 was up less than 1%. Here's why that is and also why Bristol-Myers Squibb may have a strong 2014. Great News Bristol-Myers...
Bristol-Myers Squibb Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 12, 3:46PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $54.87 to a high of $55.35. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $54.87 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.06% Sell Off
Comtex SmarTrend(R) - Wed Mar 12, 3:46PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $54.87 to a high of $55.35. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $54.87 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
BMY May 2nd Options Begin Trading
at The Street - Thu Mar 13, 10:56AM CDT
Investors in Bristol-Myers Squibb Co. saw new options become available today, for the May 2nd expiration.
Early Glance: Pharmaceuticals companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Can Gilead Dominate The HIV Drug Market Again in 2014?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 12, 5:35PM CDT
Gilead's slate of HIV drug therapies helped it capture the bulk of the market in 2013, outpacing competing therapies from Johnson & Johnson and Bristol-Myers . Sales from Gilead's HIV drugs totaled more than $9 billion last year,...
Bristol-Myers Squibb: More Than Just a Relief Rally?
Peter Stephens, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Last week was strong for shares in Bristol-Myers Squibb , which rallied 3% while the S&P 500 was up less than 1%. Here's why that is and also why Bristol-Myers Squibb may have a strong 2014. Great News Bristol-Myers...
Bristol-Myers Squibb Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 12, 3:46PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $54.87 to a high of $55.35. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $54.87 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.06% Sell Off
Comtex SmarTrend(R) - Wed Mar 12, 3:46PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $54.87 to a high of $55.35. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $54.87 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stock Market News for March 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:06AM CDT
Benchmarks finished Monday’s trading session nearly flat after recovering from day’s initial losses caused due to a drop in China’s export data and less-than-expected growth in Japan’s economy
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
